BioCentury | Apr 18, 2016
Clinical News

ParvOryx: Phase I/IIa started

...receive IV ParvOryx on 4 consecutive days followed 6-13 days thereafter by an intrametastatic dose. Oryx GmbH & Co. KG...
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

...Rochester, Minn. Oncolys BioPharma Inc. (Tokyo:4588), Tokyo, Japan Oncolytics Biotech Inc. (TSX:ONC; OTCQX:ONCYF), Calgary, Alberta Oryx GmbH & Co. KG...
BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

...how oncolytic viruses interact with cancer cells. At least two companies, Oncolys BioPharma Inc. and Oryx GmbH & Co. KG...
BioCentury | Sep 21, 2015
Clinical News

VicOryx: Phase I started

...site at weeks 1, 9, 17 and 25 to test for delayed time hypersensitivity response. Oryx GmbH & Co. KG...
BioCentury | Jul 13, 2015
Clinical News

ParvOryx: Phase I/IIa data

...primary or recurrent glioblastoma showed that ParvOryx was safe and induced “strong” cellular immune responses. Oryx GmbH & Co. KG...
BioCentury | May 25, 2015
Clinical News

MicOryx: Additional Phase I/IIa data

...that MicOryx was safe and induced humoral and cellular immune responses (see BioCentury, March 16). Oryx GmbH & Co. KG...
BioCentury | Mar 16, 2015
Clinical News

VicOryx: Phase I/IIa data

...4 weeks of an 8-week cycle was safe and induced humoral and cellular immune responses. Oryx GmbH & Co. KG...
BioCentury | Mar 16, 2015
Clinical News

MicOryx: Phase I/IIa data

...received standard chemotherapy showed that MicOryx was safe and induced humoral and cellular immune responses. Oryx GmbH & Co. KG...
Items per page:
1 - 8 of 8
BioCentury | Apr 18, 2016
Clinical News

ParvOryx: Phase I/IIa started

...receive IV ParvOryx on 4 consecutive days followed 6-13 days thereafter by an intrametastatic dose. Oryx GmbH & Co. KG...
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

...Rochester, Minn. Oncolys BioPharma Inc. (Tokyo:4588), Tokyo, Japan Oncolytics Biotech Inc. (TSX:ONC; OTCQX:ONCYF), Calgary, Alberta Oryx GmbH & Co. KG...
BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

...how oncolytic viruses interact with cancer cells. At least two companies, Oncolys BioPharma Inc. and Oryx GmbH & Co. KG...
BioCentury | Sep 21, 2015
Clinical News

VicOryx: Phase I started

...site at weeks 1, 9, 17 and 25 to test for delayed time hypersensitivity response. Oryx GmbH & Co. KG...
BioCentury | Jul 13, 2015
Clinical News

ParvOryx: Phase I/IIa data

...primary or recurrent glioblastoma showed that ParvOryx was safe and induced “strong” cellular immune responses. Oryx GmbH & Co. KG...
BioCentury | May 25, 2015
Clinical News

MicOryx: Additional Phase I/IIa data

...that MicOryx was safe and induced humoral and cellular immune responses (see BioCentury, March 16). Oryx GmbH & Co. KG...
BioCentury | Mar 16, 2015
Clinical News

VicOryx: Phase I/IIa data

...4 weeks of an 8-week cycle was safe and induced humoral and cellular immune responses. Oryx GmbH & Co. KG...
BioCentury | Mar 16, 2015
Clinical News

MicOryx: Phase I/IIa data

...received standard chemotherapy showed that MicOryx was safe and induced humoral and cellular immune responses. Oryx GmbH & Co. KG...
Items per page:
1 - 8 of 8